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A B S T R A C T
Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its
crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present
review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology,
infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common
the mechanisms through which IL-17 is considered a molecular target for the development of novel biological
therapies in these different fields. A comprehensive review of the literature and analysis of the most outstanding
evidence have provided the basis for discussing the most relevant data related to IL-17A blocking agents for the
treatment of different disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondy-
litis, cardiovascular disorders, non alcoholic fatty liver disease, multiple sclerosis, inflammatory bowel disease,
uveitis, hematological and solid cancer. Current controversies are presented giving an opening line for future
research.
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The IL-17 family of cytokines consists of 6 proteins (IL-17A to IL-
17F) and 5 receptors (IL-17RA to IL-17RE) which are structurally un-
related to any other known cytokine receptor (Fig. 1) [1]. IL-17A and
IL-17F are produced by several types of immune cells, while IL-17B, IL-
17C and IL-17D are mostly produced by epithelial cells. IL-17 receptors
are widely distributed across common cell types at different tissues.
Depending on the nature of the responder cell, the ligation of IL-17R
initiates signaling pathways leading to activation of the transcription
factors NFκB, IκBζ, AP1 and C-EBP, which induce transcription of
several genes in a tissue-specific fashion [3]. Among the most relevant,
inflammatory cytokines (TNF, IL-6, IL1β, G-CSF, GM-CSF), chemokines
(IL8, CXCL1, CXCL2, CXCL5, CCL2, CCL7, CCL20), matrix metallopro-
teinases (MMP1, MMP3, MMP9, MMP12, and MMP13), and also dif-
ferent proteins to preserve epithelial barrier function such as bacter-
icidal peptides (cathelicidins, α and β defensins), claudins and mucines
[4] (Table 1).
Despite its proinflammatory effect, IL-17A and IL-17F alone are not
powerful inflammatory cytokines. In fact, its potent inflammatory ac-
tion is mostly related with its capability to recruit immune cells, and
with its synergistic actions with other proinflammatory cytokines such
as TNF, IL-1β, IFNγ, GM-CSF, IL-22 [5]. By recruiting and activating
neutrophils, and at lesser extent monocytes, IL-17A and IL-17F cyto-
kines are central players in the physiological immune response against
extracellular bacteria and fungi. Its protective function is mostly re-
levant at mucosal surfaces and skin where, upon appropriate stimuli, IL-
17 cytokines are immediately released and contribute to epithelial
homeostasis, to inflammatory acute responses and B cell stimulation
[6], thus acting as a bridge between innate and acquired immune re-
sponses.
IL-17A is the hallmark of the Th17 subset of CD4 lymphocytes,
which also produce IL-17F, IL-22 and IL-21. Th17 differentiation is
dependent on the presence of proinflammatory IL-6 and IL-1β, but
surprisingly also TGFβ, an anti-inflammatory cytokine produced by
several non-immune cells. Th17 differentiation requires simultaneous
activation of the transcription factors STAT3 (IL-6 dependent) and
ROR-c (TGFβ-dependent). After differentiation, Th17 express IL-23-R
and require IL-23 for proliferation and survival. However, it is now
recognized that IL-17 is also produced by CD8 lymphocytes and by
tissue-resident innate cells such as NK, NKT, Tγδ, and ILC3 lympho-
cytes, which are rapidly activated after injury or infection to secrete IL-
17 in an HLA-independent fashion. In fact, from an evolutionary per-
spective, IL-17 is an ancient cytokine already identified in lampreys
with little evolutionary variation over 360 million years and therefore
lacking an adaptive immune system [7]. Production of IL-17A by
myeloid cells (neutrophils, mastocytes) is controversial due to its cap-
ability for extracellular environmental IL-17A endocytosis [8]. Whether
IL-17 production by the different types of innate immune cells is strictly
IL-23-dependent is a matter of intensive debate [9–11]. In this sense, it
has been shown that in persistent psoriatic manifestations and psoriatic
arthritis, innate immune cells can be a non-IL-23 dependent source of
IL-17A, which can contribute to the pathogenesis of these diseases [12].
In the same way that monogenic defects in the IL-17 pathway – as
observed in Hyper-IgE syndrome, chronic muco-cutaneous candidiasis
and APECED syndrome – are associated with increased susceptibility to
infections mainly by Candida sp. and Staphylococcus aureus [13], un-
restrained IL-17 production has been demonstrated to be involved in
the pathogenesis of several chronic inflammatory disorders, as well as
organ-specific autoimmune diseases. Notwithstanding basic intensive
research, several gaps in the knowledge of the pathogenic role of IL-17
cytokines exist. Among them, two important uncertainties have already
emerged. First at all, the relevance of distinctive IL-17-producing cells
and how they are locally activated in different pathologies is just be-
ginning to be explored. For instance, ILC3 seems to be the key IL 17-
producing cell at the enthesis in SpA [14], while tissue-resident
memory CD8 T constitute the majority of intradermal T cells in psor-
iatic plaques [15]. Secondly, the role of Th17 cells in human diseases is
difficult to establish because they do not display a terminal differ-
entiation phenotype, but characteristically exhibit instability, plasticity,
and functional heterogeneity, including pathogenic and non-pathogenic
phenotypes. The distinctive features of the various Th CD4 effector/
regulatory subpopulations are determined largely by the set of lineage-
specific transcription factors they express and the cytokine genes they
transcribe. The induction of the distinctive patterns of gene expression
is dependent on the local cytokine milieu during the antigen-presenting
cell mediated activation of a naïve T cell (Th0) (Fig. 2). Moreover, ti-
sular factors such as dysbiosis, pH modifications or dietary intakes, by
exerting epigenetic changes, can further promote transitory changes in
Th differentiation programs [16]. Thus, Th17 cells expressing their
Fig. 1. IL-17 Cytokine and receptor families [2].Note added in proof: it has recently been identified that IL17RB also uses ILRA chain for signal transduction of type 2
cytokines[184].
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signature transcription factor ROR-c and secreting IL-17A can si-
multaneously co-express Tbet and secrete also IFN-γ (dual Th lym-
phocytes) (Fig. 2). Moreover the pro-inflammatory ROR-c Th17 cell
producing IL17 can simultaneously transcribe Fox-P3 and thus achieve
the capability to co-produce IL10, an anti-inflammatory cytokine (15).
In healthy individuals, the majority of Th17 cells are nonpathogenic
and found at mucosal sites where they promote tissue repair and con-
tribute maintain barrier functions. It would therefore make sense that
the default Th17 differentiation program would favor a nonpathogenic
phenotype that could be converted into a pathogenic phenotype in
presence of additional proinflammatory signals, such as IL-1β or IL-23
[17].
Targeted manipulation of the immune system in animal models has
led to insights into disease pathogenesis, but is contribution to for-
mulate clinical and therapeutic concepts in humans has been much
more limited [18]. Thus, in experimental animal models of chronic
inflammatory diseases such as posterior uveitis, psoriasis, inflammatory
bowel disease, multiple sclerosis, collagen-induced arthritis and anky-
losing spondylitis, IL-17A appeared to be a crucial pathogenic molecule.
However, results of clinical trials with anti-IL-17 antibodies in Crohn
disease, RA and refractory posterior uveitis have been discouraging or
only partially effective in spite of strong evidence for a dominant pa-
thogenic role of IL-17A in Crohn [19,20], RA [21] and posterior uveitis
[22,23] (Table 2). On the other hand, IL23/IL17 blockade is highly
effective in Psoriasis, Ankylosing Spondylitis and Psoriatic arthritis, and
therefore a few monoclonal antibodies selectively acting at different




The central role of IL-23/Th17 axis in the pathogenesis of psoriasis
has been the focus of extensive research. Selective antagonists to IL-23,
IL-17, IL-22, IFNγ, and IFNα have been examined as therapeutic targets.
Although several isoforms of IL-17 have been identified, IL-17A is the
best characterized from a functional and pathogenic perspective.
Blockade of IL-17A (ixekizumab and secukinumab), the IL-17 receptor
A subunit (brodalumab) or IL-23p19 (guselkumab, risankizumab, til-
drakizumab, mirikizumab) can reverse clinical, histologic, and mole-
cular features of psoriasis. In contrast, IL-22 and IFN-γ have a smaller
pathogenic role, given that single antagonism of these cytokines with
neutralizing antibodies has not been associated with marked clinical
improvement, highlighting the predominant pathogenic role of the IL-
23/IL-17 axis in patients with psoriasis [31].
Blocking IL-17A with targeted treatments might be more far-
reaching than previously thought, and evidence is accumulating that
cells of the innate immune system, like neutrophils, mast cells, γδ T
cells and innate lymphoid cells (ILC3) might also be an important
source of IL-17A in psoriasis [32]. Relevant finding is the presence of
cells other than T lymphocytes (most likely innate immune cells) ex-
pressing IL-17A independently from IL-23 in psoriatic plaques re-
fractory to ustekinumab therapy [33].
However, activated monocytes and T lymphocytes have been sug-
gested to be the dominant source of IL-17A rather than neutrophils
[34]. Moreover, it has also been demonstrated that clinically resolved
psoriatic plaques contain psoriasis-specific IL17-producing long-lasting
resident memory T CD4 and T CD8 clones [35].
Recent studies have provided interesting clinical data on drugs
targeting the IL-17-Th17 pathway. In a head-to-head, double-blind
study, secukinumab demonstrated sustained superior efficacy than us-
tekinumab in clearing skin of subjects with moderate-to-severe plaque
psoriasis through week 52, with greater reductions in psoriasis-related
pain, itching, and scaling, and greater improvement across all quality-
of-life measures evaluated, with a favorable safety profile [36]. Also,
treatment with secukinumab 300mg at a fixed-interval schedule (every
4 weeks) has demonstrated sustained efficacy in achieving ≥ 90%
Fig. 2. Th differentiation patterns. After antigen
processing, dendritic cells are activated and start
secreting specific cytokines and present antigen
peptides in a HLA-dependent fashion to Th0 naïve
cells. According to the factors present at the im-
munological synapse, Th0 initiate a program of
lineage-specific transcription factor (TF) expression
which allows for transcription of genes characteristic
of each Th differentiation pathway: Tbet=Th1; Gata-
3=Th2; ROR-γT (ROR-c) = Th17; Fox-P3= Treg.
However, depending on the local tisular and cyto-
kine milieu, simultaneous transcription of more than
a TF is possible, allowing for more than one lineage-
specific cytokine production (“Dual“ Th cells). This
possibility may render a Th17 cell pathogenic or not
pathogenic.
Table 1
IL-17 functions in homeostatic conditions.
Molecule Actions
IL-17 A − Stimulate the production of neutrophils
− Potent chemotactic effect on neutrophils (and monocytes)
− Production of mucus
− Production of antimicrobial peptides
− Epithelial integrity with secretion of claudins
− Production of inflammatory chemokines/cytokines
IL-17 F
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improvement in Psoriasis Area and Severity Index (PASI 90) and in
overall and subscale scores on all quality-of-life instruments, which has
been maintained through 5 years with no new safety concerns [37].
Furthermore, three phase III trials have shown that ixekizumab, a
monoclonal antibody against interleukin-17A, was superior to placebo
and etanercept in the treatment of moderate-to-severe psoriasis through
60weeks of treatment [38].
Data from three prospective phase III studies of secukinumab with a
follow-up of 2.5 years demonstrated long-lasting efficacy and safety in
the complete spectrum of psoriasis manifestations, including palmo-
plantar, nail, and scalp manifestations [39]. In moderate-to-severe
genital psoriasis with ≥ 1% body surface area involved, ixekizumab
has been shown to be superior to placebo at week 12 [40].
Aiming to understand the potential of IL-17 inhibitor secukinumab
for disease modification and based on the fact that a portion of patients
did not relapse for at least 1 or 2 years post-discontinuation of secuki-
numab therapy [41], the ongoing STEPin study investigates whether
early intervention with secukinumab versus narrow-band ultraviolet B
(nb-UVB) phototherapy in subjects with new-onset psoriasis can modify
the long-term natural course of the disease and thus become a novel
treatment strategy for patients with psoriasis [42].
To test the concept of a very early intervention in PsA, recent ex-
ploratory study has shown that in psoriatic patients with arthralgia and
inflammatory changes in the joints very early treatment with secuki-
numab led to resolution of inflammation and no progression of joint
bone changes after 24 weeks [43]. However, additional research is
needed to further understand this approach.
2.2. Other diseases
IL-17A has also been linked to the pathogenesis of atopic dermatitis
(AD). In experimental AD models, IL-17A was shown to be an inducer of
Th2-mediated immune response [44,45] and to contribute to the da-
mage of skin barrier proteins, with reduced expression of filaggrin and
claudin 1 in lesional atopic skin; filaggrin expression and disease se-
verity have been found to be inversely correlated [46]. Moreover, ele-
vation of skin and serum levels of IL-17A in AD emphasizes the systemic
inflammatory profile of this dermatosis. Although IL-17A may mediate
AD-related immune dysregulation by amplifying the inflammatory re-
sponse [47], the proposal of IL-17A as an attractive target for AD is still
unclear. AD is now considered to be heterogeneous, with additional
activation of Th22, Th17/IL-23, and Th1 cytokine pathways depending
on the subtype of the disease, and the immune activation seems to
extend beyond lesional AD, since non-lesional skin and the blood
component harbor AD-specific inflammatory changes. Future therapies
should probably focus on a systemic treatment approach, especially in
patients with moderate-to-severe disease [48].
The precise pathogenesis of alopecia areata remains unknown.
However, this disease seems to be triggered by helper T cell infiltration
in hair follicles. Infiltration of CD4(+)IL-17A(+) Th17 cells in the
dermis, particularly around hair follicles was found in patients with
alopecia areata, including single patch alopecia areata, multiple patch
alopecia areata, alopecia totalis and alopecia universalis [49]. These
findings suggest that alopecia areata is induced by a Th17-associated
autoimmune mechanism. A quantitative analysis of IL-17-producing
cells in different lesional skin of several forms of alopecia areata
showed that the ratio of IL-17-producing cells in acute, diffuse and total
alopecia was significantly lower than in patchy alopecia areata. Re-
garding IL-12, IL-17, and IL-23 receptor gene polymorphisms, IL-12 and
IL-23R polymorphisms did not show a significant association with
alopecia areata, but the IL-17 GG genotype was associated with sus-
ceptibility to the disease, even though this phenotype was present in a
small number of patients [50]. Th17 cell counts have been found to be
significantly higher than those of Treg in patients with alopecia areata
(45). Furthermore, Th17 cell counts in patients with disease of short
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respective counterparts, both in lesional skin and in peripheral blood
mononuclear cells. In another study, the expression of IL-17, IL-22,
Foxp3 and B cell activating factor (BAFF), a regulator of T cell activa-
tion, was evaluated in tissue and sera of patients with alopecia areata
[51].Tissue and serum levels of IL-17, and tissue levels of IL-22 and
BAFF were significantly higher in patients with alopecia areata than in
controls. A significant positive correlation was found between both
tissue levels of IL-17 and BAFF, and tissue levels of IL-22 and disease
duration. These data draw attention to the possible synergistic in-
volvement of Th17 cells and BAFF in the pathogenesis of alopecia
areata.
In tissue samples of hidradenitis suppurativa, IL-12 and IL-23 were
found to be abundantly expressed by macrophages infiltrating papillary
and reticular dermis of lesional skin. In addition, IL-17-producing T
helper cells were found to distinctly infiltrate the lesional dermis,
suggesting the involvement of the IL-23/Th17 pathway [52]. In a study
of 86 patients with hidradenitis suppurativa and 86 matched healthy
volunteers aimed to determine serum levels of IL-17 in both groups, the
mean serum levels in patients were significantly higher than in healthy
volunteers [53]. Also, a tendency toward higher serum IL-17 con-
centrations in patients with more advanced disease was observed [53].
According to current data, anti-IL-17 agents seem promising agents
to treat hidradenitis suppurativa. An ongoing pilot study evaluates the
safety and feasibility of secukinumab for patients with moderate-to-
severe hidradenitis suppurativa, as well as informs on the effect size
that will be useful for future larger randomized control trial with an
active comparator (Clinical trial NCT 03099980).
2.3. Controversies
In addition to the previously described diseases, it has been recently
suggested a role for IL-17 in the pathophysiology of a large number of
dermatological inflammatory dermatoses, such as lichen planus, pyo-
derma gangrenosum, pemphigus vulgaris, pemphigoid, or dermatitis
herpetiformis. The potential activity of IL17A inhibitors in the control
of these diseases, as well as their long-term efficacy and safety, and
their potential for psoriatic disease modification, is a challenge for the
scientific community.
3. Rheumatology
The IL-23/IL-17/IL-22 cytokine axis has been shown to be involved
in the pathogenesis of chronic arthritis (Fig. 4) and structural damage
including bone erosion, and new bone formation in experimental
models of spondyloarthritis (SpA) [54,55].
In animal models of inflammatory arthritis (collagen-induced ar-
thritis), IL-17A gene transfer induced the expansion of IL-
17RA(+)CD11b(+)Gr1(low) osteoclast precursors and a concomitant
elevation of biomarkers indicative of bone resorption. This occurred at
a time preceding noticeable joint inflammation, suggesting that IL-17A
is critical for the induction of pathological bone resorption through
direct activation of osteoclast precursors [56]. In validated animal
models of SpA, blockade of IL-17A, but not of TNF-α, reduced clinical
manifestations, with radioimaging and histological data showing that
IL-17A blockade also impact structural damage, including pathologic
new bone formation [54,57]. Also, IL-23 has been shown to be essential
in the development of an experimental model of enthesitis acting on IL-
Fig. 3. Different targets and antagonists of the IL-23/IL-17 pathway already approved [27–30].
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23 receptor, RAR-related orphan receptor γt (ROR-γt), and stem cell
antigen 1 (Sca1)(+) entheseal resident CD4-CD3-T cells [14]. Besides
evidence from animal models, it has been showed the in vitro capacity
of IL-17A to induce differentiation of osteoblasts from synovial biopsies
of SpA patients [57]. Moreover, local, but no systemic IL-17 A, induced
polarizacion of anti-inflammatory Mesenchymal stem cells type 2
(MSC2) and bone neoformation in AS patients [58].
3.1. Psoriatic arthritis
Psoriatic arthritis (PsA) is an immune-mediated inflammatory dis-
ease belonging to the concept of spondyloarthritis which is character-
ized by a wide musculoskeletal (arthritis, enthesitis, spondylitis, dac-
tylitis) and cutaneous (skin and nail psoriasis) involvement with
extrarticular features such as bowel inflammatory disease and uveitis.
Genetically and clinically is a very heterogeneous disease [59], and its
pathophysiology, i.e, the relative expression of IL-23/IL-17 or TNF
pathways, seems to be different in the distinct tissues involved [60].
In synovial tissue and fluid samples from PsA, IL-23A mRNA ex-
pression correlated with C-reactive protein levels and swollen joint
count [61]. Although Th17 cells were reported as the pathogenic cells
implicated in animal models of arthritis, mast cells are the main cells
expressing IL-17A in synovial tissue of patients with peripheral SpA,
including PsA, while very few IL-17+ T cells were found [62]. How-
ever, mast cells do not synthesize, but rather capture IL-17A from the
extracellular medium and release it after an inflammatory/infectious
challenge [8]. Recent evidence supports the presence of IL-17A-positive
mast cells across different SpA-related target tissues (skin, gut, synovial
tissue), and the inverse correlation between its IL-17A content and in-
flammation indicate that IL-17A in mast cells can be regulated [63].
Therefore, tissue-resident mast cells may act as IL-17A-loaded sentinel
cells and release IL-17A to amplify inflammation and should therefore
be further investigated to understand how IL-17A can be controlled
locally during tissue inflammation [63].
Other IL-17 A producing cells may also have pathogenic relevance
in PsA. IL-17A+ CD8 T cells are enriched in synovial fluid of PsA pa-
tients and correlate with disease activity, power Doppler signal and
erosive disease [64]. Innate lymphocyte cells (ILC) are increased in
peripheral blood of PsA patients, and distinct changes of ILC
subpopulations are associated with clinical disease activity as well as
imaging signs of inflammation and structural damage. In clinically ac-
tive PsA, ILC3 (induced by IL-23 and synthesizing IL-17, IL-22) were
significantly increased at the expense of ILC2s (synthesize IL-4, IL-5, IL-
9 and IL-13), supporting the concept of IL-23/IL-17 pathway activation
is also the driving force of inflammation in PsA patients [65,66].
Although IL-23 is needed to the development of Th17 and Tc17 cells
as well as to induce IL-17 and IL-22 production of innate immune cells
expressing the IL-23-receptor, there are many other innate immune
cells producing IL-17 in an IL-23-independent manner. Depending of
the predominance of the subtype of IL-17A expressing cell in the dif-
ferent tissues (gut, skin, musculoskeletal, etc) in PsA or AS patients, IL-
23 or IL-17A targeted therapies could be or no efficacious. Studies on
expression of IL-23/IL-17 cytokine axis are warranted to better define
the more convenient target.
In patients with active PsA treated with secukinumab, the extension
phase of the FUTURE 1 trial [67], confirms long term (156weeks) ef-
ficacy in all endpoints, including (American College of Rheumatology)
ARC20 response, quality of life, and radiographic progression [68].
ARC20/50/70 responses were sustained through 5 years of treatment
[69]. On the other hand, the first RCT evaluating the efficacy of a
biologic treatment in the management of axial manifestations in pa-
tients with PsA recently demonstrated rapid and significant improve-
ment in ASAS20 response through Week 12 of secukinumab vs. placebo
[70].
The PSARTROS study was designed to elucidate the effects of IL-17A
inhibition on inflammation and bone changes in joints affected by PsA
[71]. In this open-label study, 20 patients with PsA received 24-week
treatment with secukinumab, which led to significant improvement of
synovial inflammation (MRI, power Doppler ultrasound, and high-re-
solution peripheral quantitative computer tomography [72] of the
hands), with no progression of catabolic and anabolic bone lesions.
3.2. Ankylosing spondylitis
In ankylosing spondylitis (AS), serum concentrations of IL-23 are
elevated and polymorphisms in the IL-23 receptor are associated with
AS and PsA. Other studies have shown increased numbers of circulating
Th17 cells in the peripheral blood of patients with SpA, included AS,
Fig. 4. The inflammatory cascade resulting in the production of IL-17 cells originates in the macrophages and dendritic cells. Several types of cells of the innate and
adaptive immune systems produce IL-17 which along IL-22 is involved in bone neoformation. *There is no clear evidence of IL-23R expression; IL, interleukin; ROR,
RAR-related orphan receptor; Tc, cytotoxic T cell; Th, T-helper cell; TNF, tumor necrosis factor.
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which were also polyfunctional in terms of T cell receptor-driven cy-
tokine production [73]. In addition, peripheral blood levels of Th22 and
Th17 cells were reported to be elevated in patients with AS [74].
Dysbiosis is reported as the inducer of subclinical gut inflammation
and production of IL-23 which actives ILC3, which are proposed to
migrate to the joints where they may trigger inflammation and bone
neoformation through IL-17 and IL-22 release [75].
Results from clinical trials support the efficacy and safety of agents
that block IL-17 (secukinumab and ixekizumab) in AS patients [76]. In
a 3-year extension study of the randomized MEASURE 1 trial [76] in
274 patients with AS, secukinumab provided sustained efficacy in signs,
symptoms and physical function, without new safety signals [77]. The
efficacy and safety of secukinumab has been confirmed in 80% of pa-
tients who entered in the extension study and completed 5 years of
treatment [78]. In patients with AS treated with secukinumab for
2 years (weekly after 4 weeks and every 4 weeks thereafter), improve-
ment in pain and fatigue scores were documented, which were noted in
both subgroups of patients with hsCRP elevated or normal baseline
values, as well as in anti-TNF-naïve patients or with TNF inadequate
response [77].
Unexpectedly, neither risankizumab nor ustekinumab IL-23 an-
tagonists, have shown efficacy in phase II study in patients with AS
[25], challenging the pathogenic role attributed to IL-23 in animal
models of SpA [14] and providing evidence of the distinct roles of IL-
23/IL-17 axis components in the different tissues of different SpA
conditions.
3.3. Rheumatoid arthritis
High levels of serum IL-17 A and increased number of Th17+ cir-
culating cells have been reported in RA. As in PsA, in RA synovial tissue
mast cells are the main IL-17A+ cells, with less proportion of IL17A+
neutrophils and very few IL17A+ T cells. Peripheral blood levels of
Th22 and Th17 cells were elevated and correlated with disease activity
in patients with RA [74].
In a phase 3 randomized double-blind clinical trial, the anti-IL-17A
antibody, secukinumab, at a dose of 150mg resulted in improvement in
signs and symptoms and reduced disease activity in patients with active
RA who had an inadequate response to TNF inhibitors [79]. However,
treatment with ustekinumab (anti-IL-12/23 p40 antibody) or guselk-
umab (anti-IL-23 antibody) did not significantly reduce the signs and
symptoms of RA [26].
The modest response of RA to secukinumab could perhaps be ex-
plained by disease heterogeneity. Interestingly, the subgroup of RA
patients with synovial tissue ectopic lymphoid neogenesis (ELN) had a
robust expression of IL-23 and its downstream cytokines, IL-17F, IL-22
and IL-21. This observation raises the question of whether in the group
of patients with synovial ELN, targeting this pathway may specifically
provide larger clinical benefits [80].
3.4. Controversies
Although IL-23 is needed for development of Th17 and Tc17 cells as
well as to induce IL-17 and IL-22 production by innate immune cells
expressing the IL-23-receptor, there are many other innate immune
cells producing IL-17 in an IL-23-independent manner. Depending on
the predominance of the subtype of IL-17A producing cell in the dif-
ferent tissues (gut, skin, musculoskeletal, etc) in PsA or AS patients
and/or the clinical stage, IL-23 or IL-17A targeted therapies could be or
no efficacious [81].
As an example, experimental models support the key pathogenic
role of IL-23 in the development of enthesitis, spondylitis, bone neo-
formation and erosions through IL-23R+RORgt+CD3+CD4-CD8- en-
thesitis-resident cells [14]. In axial tissues of AS patients, it has been
demonstrated that IL-23/IL-17 producing cells are macrophage and
dendritic cells expressing IL-23 and myeloid cells (neutrophils)
expressing IL-17A. Despite of these findings, clinical trials confirms that
only TNF and IL-17 A are effective therapeutic targets in AS [25].
4. Hepatology
Liver is one of the main producers of IL-17A [82] and IL-17RA is
thoroughly expressed in liver cells as hepatocytes, sinusoidal cells,
biliary cells, and stellate cells [82,83]. In mouse models, IL-17A
blockade (genetic deletion or antibody neutralization) protects from
liver injury [84] whereas its administration increases liver damage
[85]. In humans, IL-17A has been studied in hepatitis B [86] and C
[87], alcohol [88], primary biliary cholangitis [89], acute rejection in
liver transplant [90], hepatocellular carcinoma [91], autoimmune he-
patitis [92], and primary sclerosing cholangitis [92]. In all of them, the
IL-17 axis is overexpressed and its blockade is suggested as of future
therapeutic benefit [83,86–92].
Nowadays, the focus of interest is shifting to non-alcoholic fatty
liver disease (NAFLD) as it has become the most important and severe
liver disease leading to liver transplant [93,94]. NAFLD is characterized
by excessive hepatic fat accumulation defined by the presence of stea-
tosis in> 5% of hepatocytes [95] and is considered the hepatic mani-
festation of the Metabolic Syndrome [95]. Other non-related diseases to
Metabolic Syndrome can provoke fatty liver, as excessive alcohol con-
sumption, and infrequent genetic diseases [95]. A strong association is
recognized in the last years between fatty liver and psoriasis so that
these patients suffer a higher prevalence and severity of both when they
coexist [96].
NAFLD pathogenesis is complex and multifactorial. The disease is
the final result of the not yet perfectly understood interaction between
lifestyle (diet, physical activity) and genetic background [96–98]. In-
sulin resistance is the key factor linking Metabolic Syndrome and
NAFLD [99]. The liver is influenced by peripheral insulin resistance,
mainly mediated by proinflammatory cytokines as TNFα, IL-6 and IL-17
[99]. But the liver is also influenced by a specific process of intrahepatic
insulin resistance mediated by an excess of free fatty acids released
from adipose tissue that became lipotoxic inducing accumulation of
hepatic diacylglycerols and activation of inflammatory pathways that,
in turn, inhibit insulin signaling and lead to hepatic insulin resistance
[99]. IL-17 plays a central role in this inflammatory hepatic response
[100]. There is an increase in IL-17 production driven by natural killer
(NK), natural killer T (NKT), and Th17 cells. NK cells represent one
third of liver lymphocytes and are the main source of liver IFNγ [100].
They have been shown to be involved in fatty liver progression [101].
NKT are also an important part of liver immunity as producers of IFNα,
IFNγ, and IL-17 [102]. NKT cells modulate fibrogenic and inflammatory
responses in liver tumors, autoimmune hepatitis and viral hepatitis
although its role in NAFLD is yet unclear [102]. Th17 cells are the
primary source of IL-17 [103]. Obesity drives increased levels of Th17
cells and IL-17 production whose levels are increased in fatty liver
[104]. Increased levels of IL-17 induced by NK, NKT and Th17 cells
activate IL-17AR in a subset of liver cells, mainly hepatocytes, Kuppfer
cells, and hepatic stellate cells. Triglyceride-stored hepatocytes in
NAFLD are more susceptible to stress damage [105]. IL-17 over-
expression further increases hepatocytes lipid uptake aggravating da-
mage and rendering hepatocytes prone to cell death and disease pro-
gression [105]. Kuppfer cells play a critical role in liver homeostasis as
regulators of hepatic pathogenesis via activation of inflammation (IL-6,
IL-12, TNFα) [106]. The stimulation of Kuppfer cells by IL-17 results in
intense production of IL-6 and TNFα [107] and its depletion protects
from liver damage [85]. IL-17- activated Kuppfer cells augment liver
fibrosis [107]. Hepatic stellate cells (HSC) are the main source of ex-
tracellular liver matrix, and hyperactivation induces liver fibrosis in
almost all liver disorders [108]. IL-17 induced by Th17 cells and
Kuppfer cells, in turn induced by IL-17, provoke HSC collagen pro-
duction [107]. The IL-17 -mediated activation of hepatocytes, Kuppfer
cells, and HSC leads to further proinflammatory cytokine and
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chemokine production, neutrophil recruitment, reactive oxygen species
production and increased collagen deposition, processes known to
mediate NAFLD progression [100]. IL-17 excess in fatty liver is also
related to hepatocellular carcinoma risk. Unconventional prefoldin
RPB5 interactor (URI) is a chaperone involved in cell signaling, tran-
scription processes, and DNA damage; it has been described in several
tumors. Overexpression of IL-17-induced URI has been associated to
NASH and hepatocellular carcinoma and its blockade decreased liver
tumor risk.
NAFLD lacks specific treatment [95]. Patients are advocated to lose
weight by hypocaloric diet and aerobic exercise, although this goal is
rarely achieved [109]. IL-17 is relevant in the control of many immune-
mediated diseases and therefore is an attractive candidate for NAFLD
treatment. Nevertheless, the evidence is still scarce although promising.
IL-17 blockade restores insulin resistance and prevents NAFLD in-
flammation in mouse models [110]. The genetic ablation of IL-17RA
also alleviates NAFLD [110]. In another mice model, IL-17 blockade
attenuated liver damage induced by lipopolysaccharide in baseline
normal livers as much as in fatty liver, evaluated by transaminase levels
as well as by liver biopsy. Statins have been shown to reduce liver in-
flammation in NAFLD [111]. Some studies highlight the im-
munomodulatory capacity of statins by inhibiting the differentiation of
Th17 cells and decreasing its production [112,113]. Vitamin D levels
are reduced in NAFLD, increasing its severity and fibrosis [114]. Vi-
tamin D participates in modulation of IL-17 axis [114] and its supple-
mentation in NAFLD reduces liver fibrosis, inflammatory response, and
insulin resistance [115]. Considering the key role in NAFLD, IL-17 in-
hibitors could have a protective effect in NAFLD. In experimental
models they improve hepatic steatosis [116] and could block the shift
from steatosis to steatohepatitis [117], although clinical studies are still
lacking.
4.1. Controversies
Blockade of IL-17 axis needs to show clinical benefit in NAFLD
beyond basic investigation. Prospective, well-designed trials are eagerly
awaited. The main focus is probably psoriasis patients with NAFLD, as
they constitute a human model of IL-17-mediated systemic
inflammatory chronic disease.
5. Cardiology
There is evidence that Th17 cell response has a relevant role in
several cardiovascular diseases [118,119]. Interestingly, in a model of
IL-17−/− mice, hypertensive response to angiotensin II infusion was
not sustained as compared with C57BL/6J wild type mice, which in-
dicates that IL-17 is required for maintenance of angiotensin II-induced
hypertension [118]. Also, IL-17 deficiency abrogated vascular con-
traction of phenylephrine, with alterations in vascular tone thought to
be at least partly mediated by alterations in superoxide production. IL-
17 levels are increased in human hypertension as shown in a study of
type 2 diabetic patients with and without hypertension, in whom IL-17
levels in normotensive individuals were significantly lower than in
those with hypertension [118]. Therefore, it may be plausible that
targeting IL-17 and Th17 cells might help to control blood pressure and
preserve vascular function without affecting global immunity.
Over the past few years our understanding of the importance of
adaptive immunity in acute coronary syndromes (ACS) has con-
siderably increased. Profound abnormalities have been observed in
specific subsets of CD4+T cells, including type 1 helper T (Th1) cells,
CD4(+) CD28(null) T-cells, and naturally occurring regulatory T-cells
(Treg cells) [120]. The relevance of IL-17 to human atherosclerosis
remains poorly defined because of conflicting results in animal studies.
While some studies have suggested a proatherogenic role for IL-17, an
atheroprotective role for IL-17 through cross-regulation of IFN-γ-pro-
ducing Th1 cells has also been proposed. IL-17 exerts proatherogenic
effects by inducing the production of cytokines, chemokines, and matrix
metalloproteinases. IL-17 also promotes G-CSF-mediated granulopoiesis
and the recruitment of immune cells. Moreover, IL-17 induces apoptosis
of endothelial cells and cardiomyocytes by activating caspase-3 and
caspase-9, and up-regulating the Bax/Bcl-2 ratio [120]. The ather-
oprotective effect of IL-17 seems to be mediated at least in part by the
regulation of other cytokines (reduction of IFN-γ and enhancement of
IL-5) and by its inhibitory effect on VCAM-1 expression, an adhesion
molecule mediating the accumulation of monocytes and T-cells within
the lesions [120].
It has been shown that IL-17A contributes to myocardial ischemia/
reperfusion (I/R) injury by regulating cardiomyocyte apoptosis and
neutrophil infiltration (Fig. 5) [121].
In a mouse model of left coronary artery ligation and reperfusion,
IL-17A was demonstrated to play a critical role in mediating I/R [122].
It was found that myocardial infiltrated γδ T lymphocytes, but not Th17
cells, were a major source of IL-17A. Anti-IL-17A monoclonal antibody
treatment or IL-17A knockout markedly ameliorated I/R injury, which
was associated with a reduction in cardiomyocyte apoptosis and neu-
trophil infiltration, but repletion of exogenous IL-17A induced the op-
posite effect. These data suggest a novel IL-17A-dependent pathway by
which the immune system may influence the myocardial I/R injury.
Control of IL-17A production may be of benefit for minimizing I/R-
associated myocardial damage.
In a study that investigated the relationship between serum levels of
IL-17 and the risk of cardiovascular events in 981 patients enrolled in a
prospective French registry of myocardial infarction, serum levels of IL-
17 were associated with the risk of all-cause death and recurrent
myocardial infarction at 2 years, with levels of IL-17 below the median
indicative of a worse outcome [123]. It was also shown that the effect of
IL-17 remained significant after adjusting for known cardiovascular risk
factors, C-reactive protein, and treatments including statins. IL-17 in-
hibited mononuclear cell adhesion to endothelium and reduced en-
dothelial vascular cell adhesion molecule (VCAM-1) expression. At
2 years, 43% of death and myocardial infarction occurred in patients
with low (below the median) baseline IL-17 and high (above the
median) baseline sVCAM-1 levels compared with 12% in those patients
with high baseline IL-17 and low baseline sVCAM-1. The corresponding
Fig. 5. Pathogenic role of IL-17 in myocardial ischemia/reperfusion injury. IL-
17 is activated by signal transducer and activator of transcription 3 (STAT3),
which in turn activates MAPK-PI(3)K/AKT leading to production of C-X-C
chemokine 1 and IL-6 causing neutrophil infiltration and cell apoptosis [121].
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hazard ratio (HR) for event rates was 4.03 (95% CI 2.48-6.55) and re-
mained significant in the Cox multivariate analysis. This study shows
that elevated levels of IL-17 are associated with a better outcome in
patients with acute myocardial infarction, supporting a protective
regulatory role of IL-17 in coronary heart disease. Moreover, the
highest risk of death and recurrent infarction observed in patients with
low levels of IL-17 and high levels of sVCAM-1, indicates an important
modulatory role of IL-17 on vascular inflammation [123]. In a recent
study by Elnabawi and cols, they analyzed the total burden of athero-
sclerotic coronary artery plaques and the plaque subcomponents by
coronary CT in 290 psoriatic patients. The plaque burden was sig-
nificantly correlated with traditional cardiovascular risk factors and
with the severity of the disease according to the PASI. A greater re-
duction in the non-calcified plaque burden and necrotic core was ob-
served in the anti-IL17 treated group, compared to other biologic
treatments (anti-IL 12/23 and anti-TNF alpha groups). These findings
highlight the importance of systemic inflammation in coronary artery
disease in psoriatic patients. The modulation of coronary plaque indices
using biologic treatment with anti-IL17 in severe psoriatic patients
shows an opportunity of reducing the cardiovascular risk in these pa-
tients [124]. Targeting the IL-17 pathways appears a promising ther-
apeutic approach in the field of atherosclerosis and acute myocardial
infarction [125].
On the other hand, IL-17A induces endothelial damage through
increased apoptosis by decreasing the mitochondrial transmembrane
potential and have a synergistic effect with TNFα on endothelial cells
leading to pro-inflammatory and pro-thrombotic responses [126]. Re-
cently, in a 52-week randomized, double-blind, placebo-controlled
study (CARIMA) in patients with plaque psoriasis without cardiovas-
cular disease, secukinumab showed a beneficial effect on cardiovas-
cular risk as improved significantly endothelial function measured by
flow-mediated dilatation [127].
IL-17A induces apoptosis in cardiomyocytes by increasing the pro-
to anti-apoptotic protein ratio (B-cell lymphoma-2-associated protein X
Bax/Bcl-2 ratio) [128] and through iNOS (inducible nitric oxide syn-
thase) activation [129]. Also, it has been suggested that immune acti-
vation and genetic polymorphisms of IL-17 genes contribute to the
pathogenesis and progression of heart failure. In a total of 1713 adult
patients with congestive heart failure and 1713 age- and sex-matched
controls, genotyping for promoter single nucleotide polymorphisms
(SNPs), rs2275913 and rs8193037 in IL-17A and rs4819554 in IL-17RA
was examined in order to determine the relationship between in-
dividual SNPs and the risk of congestive heart failure [130]. It was
found that rs8193037 in IL-17A was associated with the risk of con-
gestive heart failure after adjustment for multiple cardiovascular risk
factors including age, sex, smoking status, diabetes, hypertension, and
dyslipidemia, and this association being evident in both ischemic and
non-ischemic heart failure. In addition, rs4819554 in IL-17RA was as-
sociated with cardiovascular mortality after a follow-up of 12.7months.
This study provided evidence for an association of rs8193037 in IL-17A
with the risk of heart failure, and of rs4819554 in IL-17RA with the risk
of cardiovascular mortality [130].
It is recognized that several immune-mediated chronic in-
flammatory diseases (IMIDs) such as Psoriasis, Rheumatoid Arthritis,
Ankylosing spondylitis, Crohn, share co-morbidities including meta-
bolic syndrome and accelerated atherosclerosis, that are associated
with increased cardiovascular risks. They all are considered to harbor a
low-grade systemic inflammatory state that might be responsible for
insulin-resistance and increased cardiovascular co-morbidities. In fact,
release of pro-inflammatory cytokines ie TNF, IL-17, IL-6 and adipo-
cytokines from tissues into the circulation has been directly related with
accelerated atherosclerosis in Psoriasis [131].
5.1. Controversies
The role of IL-17A in cardiovascular risk has been suggested in
studies with cell cultures and in vivo studies. A relevant involvement of
IL-17A has been postulated in the development and maintenance of
arterial hypertension, endothelial dysfunction, myocardiocyte apop-
tosis and in the extent of myocardial infarction in ischemia/reperfusion
models. Regarding IL-17A relationship with atherosclerosis, there are
controversial aspects determined by its dual proatherogenic and anti-
atherogenic action, which in clinical models of chronic systemic in-
flammation could shift towards a preponderant proatherogenic effect
based on its synergistic action with TNTα. More clinical studies are
needed to explore the therapeutic effect of blocking IL-17A in relation
to cardiovascular risk in patients with chronic inflammatory diseases
such as psoriasis, psoriatic arteritis and ankylosing spondylitis.
6. Ophthalmology
A pathogenic role of Th17 cells in some ocular disorders, particu-
larly uveitis, has been the focus of interest in recent years. Mucientes
et al. [132] evaluated the possible influence of the IL-17A locus on
susceptibility to non-anterior uveitis. To this purpose five IL-17A
polymorphisms (rs4711998, rs8193036, rs3819024, rs2275913 and
rs7747909) were genotyped in 353 Spanish patients with non-anterior
uveitis and 1851 ethnically matched controls. A consistent association
between two of the analyzed genetic variants, rs8193036 and
rs2275913, and the presence of panuveitis and the diffuse form of the
disease was found. These data agree with the elevated levels of this
cytokine that are found in patients with uveitis, supporting a crucial
role of Th17 cells in this pathology [132].
In Behçet’s disease (BD) in which uveitis is characterized in its more
severe form by posterior or panuveitis and retinal vasculitis, a study of
37 patients with BD and uveitis showed that IFN-γ, IL-17A, TNF-α, and
high-sensitive C-reactive protein (hsCRP) were increased, with sig-
nificantly higher levels of IFN-γ and TNF-α compared to healthy sub-
jects, supporting a Th1 immune response [133]. The analysis of the
cytokine profile in the subgroup of patients to whom serum samples
were obtained during both active and inactive stages also revealed that
IFN-γ and TNF-α were significantly increased during the active stage of
the disease. Similarly, IL-17A was increased in patients with active
uveitis compared to healthy controls. However, this increase was sta-
tistically significant only in those patients without treatment, sug-
gesting the involvement of Th17 response in BD. Additionally, TNF-α
also correlated with IL-17A in these patients, supporting the idea that
BD is mediated simultaneously by both Th1 and Th17 responses [133].
Moreover, IFN-γ, TNF-α, and IL-17A levels were higher in patients
without treatment than in those with pharmacological treatment in
both active and inactive patients, and therefore it may be speculated
that successful therapies should be able to prevent recurrent in-
flammatory attacks by keeping under control the circulating levels of
these proinflammatory cytokines [133].
However, information on the efficacy of anti-IL-17A antibodies in
the treatment of non-infectious uveitis is still limited. In patients with
psoriasis (n = 36), rheumatoid arthritis (n = 52), and chronic non-
infectious uveitis (n = 16), the efficacy and safety of AIN457 (a human
antibody to IL-17A) at doses of 3–10mg/kg given intravenously (i.v.)
was investigated [134]. Efficacy for uveitis was assessed by the number
of responders defined by either vision improvement or reduction in
ocular inflammation or corticosteroid dose. Variable responses were
obtained probably due to heterogeneity in small patient populations,
differential pathogenic roles of IL-17A in these diseases, and the dif-
ferent involvement or activation of IL-17A-producing cells [134].
Results of three different randomized studies on the efficacy of se-
cukinumab in heterogeneous populations of uveitis patients (118 pa-
tients with BD uveitis, 31 patients with active, noninfectious, non-BD
uveitis, and 125 patients with quiescent, non-infectious, non-BD
uveitis), were disappointing as there were no statistically significant
differences in uveitis recurrence between the secukinumab and placebo
groups in any study, although a beneficial effect of secukinumab in
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reducing the use of concomitant immunosuppressive medication was
recorded [135]. In a randomized, double-masked, dose-ranging, phase
2 clinical trial, with 37 patients with active non-infectious intermediate
uveitis, posterior uveitis, or panuveitis who required corticosteroid-
sparing immunosuppressive therapy, secukinumab iv (30 and 10mg/
kg) compared with a standard 300mg subcutaneous dose, produced
higher responder rates and remission rates [136]. Greater activity with
i.v. dosing suggests that patients may not receive sufficient drug with
subcutaneous administration, and that high-dose i.v. secukinumab may
be necessary to deliver the drug in therapeutic concentrations [136].
The expression of Th 17-associated cytokines (IL-17, IL-23) has been
studied in a small sample of 45 patents with dry eye disease [137].
Protein and conjunctival mRNA IL17A and IL6 levels were both sig-
nificantly increased and correlated with ocular surface parameters. The
expression of IL-23 was also significantly increased but did not correlate
with ocular surface parameters. The expressions of IL-17A and IL-6 in
tears have potential to be diagnostic biomarkers for dry eye disease
[137]. In ocular surface inflammatory pathologies, namely pterygium
and inflamed juvenile conjunctival nevus (IJCN), IL-17 was im-
munohistochemically detected in all IJCN specimens and in 84% of
pterygia samples, suggesting that IL-17 blockade may have a potential
role in management of these conditions [138].
In patients with type 2 diabetes mellitus and diabetic retinopathy
(DR), the proportion of Th17 cells and IL17A production in peripheral
blood mononuclear cell (PBMC) culture were significantly increased in
patients without DR but decreased in those with DR, and were nega-
tively correlated with body mass index, duration of diabetes, and gly-
cated hemoglobin levels [139]. Additionally, vitreous fluid IL-17A le-
vels were significantly elevated in patients with DR compared with
controls. It seems that disturbances in Th17 cells and IL-17A levels
might be associated with DR.
6.1. Controversies
Nowadays, the advent of highly effective and targeted biotherapies
and the recent imaging technologies are improving the treatment and
monitoring of patients with noninfectious uveitis. A personalized ap-
proach should take into consideration patient’s characteristics and
uveitis subtypes. Clinical and experimental observations suggest that iv
IL-17A may be an attractive therapeutic target in patients with non-
infectious uveitis. However, new molecules and the design of new
clinical trials will be necessary to demonstrate its effectiveness in the
treatment of noninfectious uveitis.
7. Neurology
The effect of IL-17 cytokines in central (CNS) and peripheral ner-
vous system (PNS) inflammatory conditions is still not well defined.
Multiple sclerosis (MS) is associated with encephalitogenic Th17 cells
[140]. Recently, Th17 and IL-17 have been suggested to be involved in
the pathogenesis of post-infectious Guillain-Barre syndrome [141].
High levels of IL-17 have also been linked to depression, a frequent
comorbidity of several chronic inflammatory diseases, i.e. Psoriasis
[131].
MS is a chronic inflammatory disease characterized by the de-
struction of myelin by peripherally activated autoreactive pathogenic T
cells. In patients with MS early results showed increased expression of
IL-17 in the brain at autopsy, and abundant IL-17-expressing cells in
active CNS lesions [142,143]. In a seminal paper, Kebir et al [140]
demonstrated in MS patients high IL-17R and IL-22R expression at BBB
(blood brain barrier)- endothelial cells, and that in vitro treatment with
IL-17A and IL-22 was able to induce BBB tight junction´s disruption.
Recently Th17 subpopulations producing low amounts of IL-10 were
identified as pathogenic in MS, and IL-10 production correlated with
disease activity [144]. Further evidence for the pathogenic role of Th17
cells in MS derives from therapies. Trafficking of MOG-reactive Th17
cells from the periphery – where they are activated – into the CNS is a
recognized early event in the development of MS. Natalizumab – a
monoclonal antibody approved for severe RR MS directed to α4-in-
tegrin that blocks mononuclear cell migration across endothelial cells –
is a highly active drug that exerts its effects by inducing peripheral
accumulation of Th17, which returns to normal when relapses occur
[145].
In the experimental autoimmune encephalomyelitis (EAE), a mouse
model of the human MS where Th17-IL-17A induce disease, neu-
tralization of IL-17 results in resolution [146]. An ongoing double-
blind, placebo-controlled proof-of-concept trial with the IL-17A– spe-
cific antibody secukinumab in active relapsing-remitting multiple
sclerosis has now provided preliminary results supporting the role of IL-
17A in multiple sclerosis in humans, as they showed a substantial re-
duction of the number of new lesions revealed by magnetic resonance
imaging (EudraCT number 2009- 011626-34) [147]. In this multicenter
study carried out at 28 sites from the Czech Republic, Russia, and Uk-
raine, patients aged 18–55 years diagnosed with RRMS with stable
disease at least 30 days before inclusion and not being currently treated
disease-modifying drugs were eligible. Other inclusion criteria were the
presence of one gadolinium (Gd) enhancing MRI lesion at screening/
baseline or one relapse in the last year or two relapses in the last
2 years. The objectives of the study were to assess efficacy, safety and
tolerability. The primary endpoint was the cumulative number of
combined unique active lesions (CUAL) observed on brain MRI scans
from week 4 to week 24. Patients (n = 73) were randomized 1:1 to
secukinumab. Afterwards, patients were included in a 12-month open
extension study, in which they received secukinumab 10/mg/kg i.v.
every 4 weeks. MRI scans were obtained within 30 days prior to ran-
domization, on a monthly basis during the treatment period, and at
study completion. In relation to efficacy, a significant reduction in new
MRI lesion activity was found, including reduction in cumulative
CUALS and new T1-Gd+ lesions, with treatment benefits being ap-
parent at week 12 and sustained through week 36. Also, a trend to-
wards clinical relapse reduction in the secukinumab group was ob-
served.
In Guillain-Barre syndrome (GBS), an heterogeneous peripheral
neuropathy involving myelin and axons, recent immunological, genetic
and gene expression studies suggest evidence towards the involvement
of Th17 cells in the pathobiology of GBS. Han et al described increased
circulating Th17 cell numbers, elevated CSF IL-17 concentrations and
increased ROR-γt and STAT-3 expression in peripheral mononuclear
cells from patients with GBS [141,148].
Psoriasis and other chronic inflammatory diseases such as in-
flammatory bowel diseases and Spondyloarthropathies (IMIDs, im-
munomediated inflammatory diseases) are now recognized as diseases
in which a low-grade systemic chronic inflammatory state is associated
with the development of co-morbidities, including increased risk of
cardiovascular events and psychiatric disorders i.e depression and an-
xiety. In these patients, depression has been associated with increased
plasmatic levels of pro-inflammatory cytokines (TNF, IL-17, IL-22)
[131]. However, the role of IL- 17 in depression has not been well
characterized. Of note, a recent study using mouse models of depression
showed that administration of Th17 cells was directly correlated with
depression sensitivity suggesting that the Th17 axis may play a role in
neuro- immune interactions [149,150].
7.1. Controversies
The pathogenic role of IL17A both in experimental models of MS
(EAE) and in MS is undisputed. Despite a small proof-of-concept trial
has already been published (137), strong evidence on the long-term
beneficial effects of IL17-blockade in MS is still needed. A clinical trial
with Secukinumab was terminated early in 2016 based upon develop-
ment of another anti-IL17 monoclonal antibody with better potential
for treating MS patients (Clinical trial NCT01433250). Moreover, the
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promising results with Siponimod improving inflammation, disability
and brain atrophy in a large clinical trial in patients with secondary
progressive MS stresses the importance of further exploring the re-
lationship among inflammation and neurodegeneration to achieve the
best treatment across the entire spectrum of the MS disease (EXPAND
trial) [151]. Siponimod, an oral selective inhibitor of Sphingosine-1-
phophatase receptors 1 and 5, has an anti-inflammatory effect on
neuroinflammation because reduces pathogenic Th17 lymphocyte
egress from peripheral lymphoid tissue into the brain. In addition, and
because its ability to cross the blood-brain barrier, it can directly in-
teract with non-lymphoid brain cells i.e astrocytes, microglia, oligo-
dendrocytes and neurons, potentially exerting direct neuroprotective
effects via routes beyond its anti-inflammatory effect [152].
8. Gastroenterology
Different studies during the past decade demonstrate that IL-17/IL-
23 cytokines are overexpressed in Crohn’s disease patients, playing a
critical role in disease mechanisms. In a study of ileal biopsies from
patients with active and inactive Crohn’s disease (CD) and control
subjects, lamina propria IL-17 and IL-23-positive cells were higher in
patients with CD, both active and inactive, than in the controls.
Furthermore, IL-17A mRNA expression was increased in biopsies from
both patients with active or inactive disease, whereas fecal IL-17 mRNA
was increased only in active disease [153]. In another study of tissue
samples from patients with ulcerative colitis (UC), CD, infectious colitis,
ischemic colitis, and healthy controls, IL-17 expression evaluated by
immunohistochemical techniques was only present in IBD samples
[19]. In inflamed mucosa from active UC and CD patients, IL-17 ex-
pression was detectable in CD3(+) T cells and CD68(+) monocytes/
macrophages with a significant increase in the number of IL-17(+) cells
in active UC and CD patients as compared with inactive patients. Al-
though IL-17 was not detected in the sera from normal individuals,
infectious colitis, or ischemic colitis patients, IL-17 levels were sig-
nificantly elevated in IBD patients. In another study assessing intestinal
biopsies from 40 patients with UC, 20 with CD, and 20 healthy controls,
Th17 cells abundance and IL-17A, IL-21 and IL-22 expression were
significantly increased in active IBD patients and correlated with dis-
ease activity index and endoscopic and histological score [154]. These
results provide evidence about the important role of Th17 cells and
Th17-related cytokines in mucosal damage and disease activity in IBD.
A meta-analysis of UC and CD Genome-wide association studies
(GWAS) in more than 75,000 cases and controls revealed a total of 163
loci that meet genome-wide significance thresholds in patients with
IBD. An interesting finding was a strong association between variants in
IL-23R with susceptibility to CD, thus confirming the implication of the
IL-23/IL-17 axis in disease pathogenesis [155].
The efficacy of ustekinumab (a monoclonal antibody against IL-12/
IL-23 p40) in Crohn’s disease in different studies also supports the idea
of the involvement of the IL23/IL17 axis in the pathogenesis of IBD
[156]. Moreover, published results from an open-label extension study
with risankizumab, a monoclonal anti- IL23p19, in patients with Crohn
disease are promising [157].
Taking into account all these evidences, IL-17 neutralization, theo-
retically, could be effective in the treatment of patients with Crohn’s
disease. However, secukinumab, a human anti-IL-17A monoclonal an-
tibody, was ineffective in a double-blind, randomized, placebo-con-
trolled proof-of-concept study of 59 patients with moderate to severe
CD (secukinumab 39, placebo 20) [158]. Unexpectedly, the trial was
stopped prematurely because predefined criterion of futility was met
(≤ 90% probabilities that secukinumab reduces Crohn’s Disease Ac-
tivity Index by<40 points more than placebo). Surprisingly, higher
rates of adverse events (Candida spp. infection) were observed in the
treatment group. To explain secukinumab's lack of efficacy in IBD, it
has been postulated that overgrowth of Candida spp. might be re-
sponsible for the worsening of IBD patients, [159]. Another possible
explanation is that blocking IL-17A may interfere with the protective
function of this cytokine in the intestine, i.e. maintenance of epithelial
integrity, showing the high complexity of IL-17 biology [160]. Other
approaches neutralizing IL-17 pathway in IBD patients have also failed.
In a phase 2, randomized, double-blind, placebo-controlled, dose-ran-
ging study in patients with moderate-to-severe CD and evidence of
active inflammation, brodalumab (anti-IL-17RA antibody) provided
disappointing results, with a disproportionate number of cases of
worsening CD and no evidence of meaningful efficacy [161].
8.1. Controversies
Inhibition of IL-17 has been ineffective to induce remission in trials
of patients with Crohn's disease despite strong evidences that IL-23/IL-
17 axis plays an important role in disease mechanisms. IL-17 pathway
regulation complexity and/or fungi overgrowth could explain lack of
efficacy. Further in-depth immunological studies should investigate
intestinal pathophysiology by setting targeted molecules in the context
of its real biological network.
9. Hematology
Allogeneic stem cell transplantation (Allo-HCT) is a curative im-
munotherapy for patients with blood-related diseases [162], but graft-
versus-host disease (GvHD) remains a major cause of transplant failure
[163,164], and effective therapeutic options beyond systemic steroids
are limited. Recently, murine transplant research has shown that in
vitro differentiated Th17/Tc17 lineages cells alone could mediate
GvHD [165]. Highly in vitro purified Th17 cells are capable of inducing
lethal GvHD in a murine acute GvHD (aGvHD) model, hallmarked by
extensive cutaneous and pulmonary lesions. The majority of these Th17
cells retained the ability to produce IL-17A in an INFγ-independent
manner. Also, in a murine Allo-HCT model, targeted depletion of Tc17
cells (a subset of CD8+ T cells) early after transplant protected from
lethal aGvHD but failed to mediate graft-versus-leukemia effect [166],
suggesting that targeting these cells would not increase the relapse risk.
A study of lesional skin biopsies in patients suffering from skin
GvHD showed that distinct T-cell patterns characterized the acute and
chronic forms of cutaneous GvHD [167]. Of note, chronic lichenoid
GvHD showed a mixed Th1/Th17 response as evidenced by a pre-
dominance of Th1 (IFN-γ, IL-12/IL-23p40) and Th17 cytokines (IL-17,
IL-23p19) and a relative increase of IL-17 and IFN-γ single-producing
CD8+ T cells. These findings allow to more accurately distinguish
between GvHD manifestations, and further confirms that Th17/Tc17
might play a key role in GvHD pathogenesis.
Over the last years several strategies such as B-cell depletion, JAK1/
2 pathway inhibition, or the infusion of mesenchymal stem cells and
regulatory T-cells have been developed to treat steroid refractory
GvHD. In line with this, targeting Th17 differentiation and function
with an anti-IL-17 monoclonal antibody might be a way to provide
better control for some GvHD manifestations such as pulmonary and
cutaneous. Nevertheless, concerns have been raised regarding the use of
anti-IL-17 in the Allo-HCT setting, given the IL-10 dependent regulatory
effect of Th17 in the gut and recent reports regarding the development
of acute GvHD in IL-17 -/- knock-out murine model [168]. The in-
hibition of IL-17 in AlloHCT could be a potential therapeutic path to
treat GvHD. To date, anti-IL-17 MoAb have not been used to treat Al-
loHCT patients and its role warrants further study.
10. Oncology
Recently, the inflammatory cytokine interleukin 17 (IL-17) and the
IL-17-Th17 pathway have gained attention as promising therapeutic
targets in the immune-oncology field. Many studies have shown high
levels of IL-17 in gastric carcinoma, colorectal cancer, non-small cell
lung cancer, breast, ovarian and hematologic cancers [169–175]. The
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utility of anti-IL-17 mAb CJM112 alone or in combination with anti-PD-
1 in multiple myeloma patients is being studied in a phase I clinical trial
(NCT 03111992).
IL-17 is a double-edged cytokine that acts in a cancer-type de-
pending manner as an anti- or protumor cytokine [176]. The oncogenic
role of IL-17 is supported by studies that demonstrated an anti-apop-
totic effect in mouse breast cancer models and sustaining self-renewal
properties of ovarian cancer stem cells [174,177]. In addition, it has
shown to decrease the presence of CD4 and CD8 infiltrating cells in
tumor sites, to diminish the secretion of interferon gamma (IFN-γ) by
CD8 T cells, to increase infiltrating T-regs and to promote angiogenesis
[178], invasion and metastasis [179] recruiting tumor associated
macrophages (TAM) and myeloid-derived suppressor cells (MDSC)
[180]. On the other hand, other authors have shown opposite effects.
Indeed, the controversial role of IL-17 in cancer comes from the het-
erogeneity in how the IL-17 is measured in the different reports: as IL-
17 mRNA or protein levels by western blotting and/or ELISA, as the
presence of Th17 tumor-infiltrating T cell. However, the fact is that the
role of IL-17 in different human cancers has been studied mostly in in
vitro cell models and human xenografts while it is known that this cy-
tokine is just one of the plethora of interleukins at the interplay be-
tween cancer and the stromal cell compartment that indeed, is secreted
by several immune cells such as macrophages, dendritic cells, neu-
trophils, natural killers, CD8 and regulatory T cells, MDSC as well as
Th17 cells.
Th17 cells are key players in inflammation and autoimmune dis-
orders, but the clinical significance of their detection in the tumor
microenvironment remains unclear. Actually, compared to conven-
tional effector T cells, Th17 phenotype comprised low levels of gran-
zyme B and activation markers HLA-DR and CD25 [181]. This ob-
servation is in favor of an impossibility to initiate cytotoxic killing.
Although Th1 cells accumulate in the tumor microenvironment of most
solid tumors as compared to samples of normal tissues, distinct func-
tions regarding their ability to promote or to eliminate tumors have
been reported, and it seems that this opposite functions depend on the
features or the microenvironment, such as nature of the antigen-pre-
senting cells, presence of TGF-β, IL-1β or IL-23. These cells can mediate
antitumoral effects by their ability to recruit immune effector cells
(cytotoxic T lymphocytes, natural killer cells, dendritic cells) into the
tumor bed and they can promote tumor growth by means of angio-
genesis (production of VEGF, angiogenic chemokines) and/or through
immunosuppression (Treg conversion, myeloid-derived suppressor cell
recruitment) [182,183].
10.1. Controversies
Targeting the Th17/IL-17 signaling axis in hematological and solid
cancers is an exciting strategy in the immune-oncology field although it
remains controversial. The dual role of IL-17 observed depends on
many factors, current sources of knowledge are based in heterogeneous
experimental cancer models and the lack of data regarding IL-17 and
cancer in humans requires well-designed clinical trials to guarantee the
safety and efficacy in cancer patients.
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